The negative regulators of Wnt pathway—DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2855-2861

  Paluszczak, Jarosław ^a,b,c   Sarbak, Joanna ^a,b,c   Kostrzewska Poczekaj, Magdalena ^a,b,c   Kiwerska, Katarzyna ^a,b,c   Jarmuż Szymczak, Małgorzata ^a,b,c   Grenman, Reidar ^a,b,c   Mielcarek Kuchta, Daniela ^a,b,c   Baer Dubowska, Wanda ^a,b,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF HUMAN GENETICS   (Poland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

DNA methylation; Oral cancer; WIF1; Wnt pathway

Indexed keywords

DACH1 PROTEIN, HUMAN; DKK1 PROTEIN, HUMAN; EYE PROTEIN; REPRESSOR PROTEIN; SIGNAL PEPTIDE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR; WIF1 PROTEIN, HUMAN;

ADULT; AGED; BIOSYNTHESIS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MALE; MIDDLE AGED; MOUTH TUMOR; OROPHARYNX TUMOR; PATHOLOGY; PROMOTER REGION; SURVIVAL ANALYSIS; VERY ELDERLY; WNT SIGNALING PATHWAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; EPIGENESIS, GENETIC; EYE PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY;

EID: 84939958282     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2913-x     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22. doi:10.1038/nrc2982.
3. Paluszczak J, Baer-Dubowska W. Epigenetic diagnostics of cancer—the application of DNA methylation markers. J Appl Genet. 2006;47(4):365–75. doi:10.1007/bf03194647.
4. Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, et al. The way Wnt works: components and mechanism. Growth Factors. 2013;31(1):1–31. doi:10.3109/08977194.2012.752737.
5. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis. 2007;28(9):1851–8. doi:10.1093/carcin/bgm176.
6. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013;3(7):770–81. doi:10.1158/2159-8290.CD-12-0537.
7. Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, et al. Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol. 2008;32(6):1253–61.
8. Yeh KT, Chang JG, Lin TH, Wang YF, Chang JY, Shih MC, et al. Correlation between protein expression and epigenetic and mutation changes of Wnt pathway-related genes in oral cancer. Int J Oncol. 2003;23(4):1001–7.
9. Paluszczak J, Hemmerling D, Kostrzewska-Poczekaj M, Jarmuz-Szymczak M, Grenman R, Wierzbicka M, et al. Frequent hypermethylation of WNT pathway genes in laryngeal squamous cell carcinomas. J Oral Pathol Med off pub Int Assoc Oral Pathol Am Acad Oral Pathol. 2014. doi:10.1111/jop.12178.
10. Pannone GBP, Santoro A, Franco R, Aquino G, Longo F, Botti G. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep. 2010;24:1035–41. doi:10.3892/or_00000952.
11. Towle R, Truong D, Hogg K, Robinson WP, Poh CF, Garnis C. Global analysis of DNA methylation changes during progression of oral cancer. Oral Oncol. 2013;49(11):1033–42. doi:10.1016/j.oraloncology.2013.08.005.
12. Diaz Prado SM, Medina Villaamil V, Aparicio Gallego G, Blanco Calvo M, Lopez Cedrun JL, Sironvalle Soliva S, et al. Expression of Wnt gene family and frizzled receptors in head and neck squamous cell carcinomas. Virchows Arch Int J pathol. 2009;455(1):67–75. doi:10.1007/s00428-009-0793-z.
13. Ravindran G, Devaraj H. Aberrant expression of beta-catenin and its association with DeltaNp63, Notch-1, and clinicopathological factors in oral squamous cell carcinoma. Clin Oral Investig. 2012;16(4):1275–88. doi:10.1007/s00784-011-0605-0.
14. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF, Koontongkaew S, et al. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene. 2000;19(28):3220–4. doi:10.1038/sj.onc.1203703.
15. Rhee CS, Sen M, Lu D, Wu C, Leoni L, Rubin J, et al. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene. 2002;21(43):6598–605. doi:10.1038/sj.onc.1205920.
16. Ishida K, Ito S, Wada N, Deguchi H, Hata T, Hosoda M, et al. Nuclear localization of beta-catenin involved in precancerous change in oral leukoplakia. Mol Cancer. 2007;6:62. doi:10.1186/1476-4598-6-62.
17. Alvarado CG, Maruyama S, Cheng J, Ida-Yonemochi H, Kobayashi T, Yamazaki M, et al. Nuclear translocation of beta-catenin synchronized with loss of E-cadherin in oral epithelial dysplasia with a characteristic two-phase appearance. Histopathology. 2011;59(2):283–91. doi:10.1111/j.1365-2559.2011.03929.x.
18. Duan Y, Fan M. Lentivirus-mediated gene silencing of beta-catenin inhibits growth of human tongue cancer cells. J Oral Pathol Med Off Pub Int Assoc Oral Pathol Am Acad Oral Pathol. 2011;40(8):643–50. doi:10.1111/j.1600-0714.2011.01007.x.
19. Chang HW, Lee YS, Nam HY, Han MW, Kim HJ, Moon SY, et al. Knockdown of beta-catenin controls both apoptotic and autophagic cell death through LKB1/AMPK signaling in head and neck squamous cell carcinoma cell lines. Cell Signal. 2013;25(4):839–47. doi:10.1016/j.cellsig.2012.12.020.
20. Iwai SYA, Harada C, Hamada M, Katagiri W, Nakazawa M, Yura Y. Involvement of the Wnt-β-catenin pathway in invasion and migration of oral squamous carcinoma cells. Int J Oncol. 2010;37(5):1095–103. doi:10.3892/ijo_00000761.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.
22. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA, et al. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene. 2000;19(1):164–8. doi:10.1038/sj.onc.1203227.
23. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, et al. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics. 2013;8(12):1373–83. doi:10.4161/epi.26781.
24. Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, et al. B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell. 2010;18(5):459–71. doi:10.1016/j.ccr.2010.10.021.
25. Song HJ, Shim KN, Joo YH, Kim SE, Jung SA, Yoo K. Methylation of the tumor suppressor gene RUNX3 in human gastric carcinoma. Gut liver. 2008;2(2):119–25. doi:10.5009/gnl.2008.2.2.119.
26. Supic G, Kozomara R, Jovic N, Zeljic K, Magic Z. Hypermethylation of RUNX3 but not WIF1 gene and its association with stage and nodal status of tongue cancers. Oral Dis. 2011;17(8):794–800. doi:10.1111/j.1601-0825.2011.01838.x.
27. Marsit CJ, McClean MD, Furniss CS, Kelsey KT. Epigenetic inactivation of the SFRP genes is associated with drinking, smoking and HPV in head and neck squamous cell carcinoma. Int J Cancer J Int cancer. 2006;119(8):1761–6. doi:10.1002/ijc.22051.
28. de Freitas C-SM, Stur E, Agostini LP, de Podesta JR, de Oliveira JC, Soares MS, et al. Promoter hypermethylation in primary squamous cell carcinoma of the oral cavity and oropharynx: a study of a Brazilian cohort. Mol Biol Rep. 2012;39(12):10111–9. doi:10.1007/s11033-012-1885-4.
29. Ekizoglu S, Dalay N, Karaman E, Akdeniz D, Ozaydin A, Buyru N. LKB1 downregulation may be independent of promoter methylation or FOXO3 expression in head and neck cancer. Transl Res J Lab Clin Med. 2013;162(2):122–9. doi:10.1016/j.trsl.2013.06.001.
30. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, et al. CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther. 2010;10(7):694–9. doi:10.4161/cbt.10.7.12895.
31. Zhang S, Feng XL, Shi L, Gong CJ, He ZJ, Wu HJ, et al. Genome-wide analysis of DNA methylation in tongue squamous cell carcinoma. Oncol Rep. 2013;29(5):1819–26. doi:10.3892/or.2013.2309.
32. Gao F, Huang C, Lin M, Wang Z, Shen J, Zhang H, et al. Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res Clin Oncol. 2009;135(5):739–47. doi:10.1007/s00432-008-0508-x.
33. Kudo Y, Tsunematsu T, Takata T. Oncogenic role of RUNX3 in head and neck cancer. J Cell Biochem. 2011;112(2):387–93. doi:10.1002/jcb.22967.
34. Popov VM, Wu K, Zhou J, Powell MJ, Mardon G, Wang C, et al. The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab TEM. 2010;21(1):41–9. doi:10.1016/j.tem.2009.08.002.
35. Ogoshi K, Kasamatsu A, Iyoda M, Sakuma K, Yamatoji M, Sakamoto Y, et al. Dickkopf-1 in human oral cancer. Int J Oncol. 2011;39(2):329–36. doi:10.3892/ijo.2011.1046.
36. Yoshino M, Suzuki M, Tian L, Moriya Y, Hoshino H, Okamoto T, et al. Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers. Int J Oncol. 2009;35(5):1201–9.